ICD Research's 'BioMarin Pharmaceutical Inc.: Company Profile and SWOT Analysis' contains in depth information and data about the company and its operations. The profile contains a company overview, business description, SWOT analysis, key facts, information on products and services, financial ratios, competitor benchmarking data, details of locations and subsidiaries, plus information on key news events affecting the company.
This SWOT analysis and company profile is a crucial resource for industry executives and anyone looking to gain a better understanding of the company's business.
ICD Research's 'BioMarin Pharmaceutical Inc.: Company Profile and SWOT Analysis' report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format.
ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report.
Examines and identifies key information and issues about 'BioMarin Pharmaceutical Inc.' for business intelligence requirements
Studies and presents the company's strengths, weaknesses, opportunities (growth potential) and threats (competition). Strategic and operational business information is objectively reported
Provides analysis on financial ratios along with a competitor benchmarking section
The profile also contains information on business operations, company history, major products and services, prospects, key employees, locations and subsidiaries
Reasons To Buy
Quickly enhance your understanding of the company
Gain insight into the marketplace and a better understanding of internal and external factors which could impact the industry
Recognize potential partnerships and suppliers
BioMarin Pharmaceutical Inc. (BioMarin) develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. Its principal product portfolio includes four approved products namely Naglazyme, Aldurazyme, and Kuvan and Firdapse. The products that are under clinical trials are PEG-PAL, GALNS for Morquio Syndrome Type A and BMN-195 for Duchenne muscular dystrophy. The company is also working on a preclinical study of BMN-185, an IgA protease for IgA nephropathy, and BMN-103, a glucosidase for Pompe disease. The company operates in the US as well as in several European countries, Brazil, other Latin America countries and Turkey. BioMarin is headquartered in Novato, California, the US.